FORMULATION AND OPTIMIZATION OF BUDESONIDE COLON-TARGETED TABLETS USING CONTROLLED POROSITY OSMOTIC PUMP TECHNOLOGY

VOLETI VIJAYA KUMAR; ISMAIL Y.

doi:10.22159/ijap.2025v17i1.52544

Authors

VOLETI VIJAYA KUMAR Crescent School of Pharmacy, B. S. Abdur Rahman Crescent Institute of Science and Technology, GST Road, Vandalur, Chennai-600048, Tamil Nadu, India https://orcid.org/0000-0003-4735-3105
ISMAIL Y. Crescent School of Pharmacy, B. S. Abdur Rahman Crescent Institute of Science and Technology, GST Road, Vandalur, Chennai-600048, Tamil Nadu, India https://orcid.org/0000-0003-4735-3105

DOI:

https://doi.org/10.22159/ijap.2025v17i1.52544

Keywords:

Design of experiments, CPOP tablets, Box-behnken design, ANOVA test, Enteric coating, Semipermeable membrane, Polysaccharides

Abstract

Objective: Formulation and optimization of Budesonide (BDU) controlled porosity osmotic pump tablets (CPOP) to treat Nocturnal Asthma (NA) by adopting the Quality by design approach was set as objective of this research work.

Methods: Solubility of Budesonide was enhanced by converting in to the form of BUD Solid dispersions, using poloxamer 188. Controlled Porosity Osmotic pump (CPOP) tablets of budesonide were formulated by wet granulation technique. Quality by design approach using Box-Behnken design was adopted to optimize the selected critical factors. The optimized formulation was compared with the marketed extended-release formulation.

Results: The percentage of drug released at 4 h (D4), 7 h (D7), and 10 h (D10) were identified as response factors during the optimization phase. Statistical analysis showed that a combination of 200 mg of the SPM coat, 19.72 mg of Eudragit S 100 for the enteric coating, and 69.74 mg of guar gum in the core could achieve drug release rates of 9.4% after 4 h, 55.9% after 7 h, and 96.6% after 10 h of administration for the CPOP tablets.

Conclusion: The results indicated that the CPOP tablets were successfully formulated for colon-targeted drug release.

Downloads

Download data is not yet available.

References

Paudel KR, Jha SK, Allam VS, Prasher P, Gupta PK, Bhattacharjee R. Recent advances in chronotherapy targeting respiratory diseases. Pharmaceutics. 2021;13(12):2008. doi: 10.3390/pharmaceutics13122008, PMID 34959290.

Venkataswamy NL. Review article on pulsatile drug delivery system. Asian J Pharm Clin Res. 2021 Jun 6;14(6):48-59. doi: 10.22159/ajpcr.2021.v14i6.41476.

Vimal Raj E, Ubaidulla Uthumansha. A current update and future prospects of chronomodulated drug delivery approaches. Afr J Biogr. 2024;6(15):276-86. doi: 10.48047/AFJBS.6.15.2024.275-291.

Richard B, Tim H, Stefan P, Per G, Angus H, Thomas B. Evaluation of budesonide formoterol for maintenance and reliever therapy among patients with poorly controlled asthma systematic review and meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e220615.

Mogal RT, Galgatte UC, Chaudhari PD. Floating pulsatile drug delivery of ranitidine hydrochloride for nocturnal acid breakthrough: design optimization in vitro and in vivo evaluation. Int J Pharm Pharm Sci. 2013;5(3):722-7.

O Donnell S, O Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1(4):177-86. doi: 10.1177/2040622310379293, PMID 23251737.

Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol. 1999;104(4):S175-83. doi: 10.1016/S0091-6749(99)70059-X.

Behera R, Sethi S. Association of upper GI bleed in patients with budesonide and SSRI therapy in chrons disease: a comparative clinical study. J Med Sci Clin Res. 2019;7(6):139-47. doi: 10.18535/jmscr/v7i6.26.

Radke R, Jain K. Enhancement of solubility and bioavailability of bcs class-II ambrisentan: in vitro, in vivo and ex vivo analysis. Int J App Pharm. 2022;14(1):67-74. doi: 10.22159/ijap.2022v14i1.43347.

Campos JC, Ferreira DC, Lima S, Reis S, Costa PJ. Swellable polymeric particles for the local delivery of budesonide in oral mucositis. Int J Pharm. 2019 Jul 20;566:126-40. doi: 10.1016/j.ijpharm.2019.05.057, PMID 31129342.

Jain SK, Jain A. Target specific drug release to the colon. Expert Opin Drug Deliv. 2008;5(5):483-98. doi: 10.1517/17425247.5.5.483, PMID 18491977.

Jayendrakumar P, Shalin P, Shwetaben P. Comprehensive review on osmotic drug delivery system. WJPR. 2021 Apr;10(5):523-50. doi: 10.20959/wjpr20215-20303.

Keraliya RA, Patel C, Patel P, Keraliya V, Soni TG, Patel RC. Osmotic drug delivery system as a part of modified release dosage form. ISRN Pharm. 2012;2012:528079. doi: 10.5402/2012/528079, PMID 22852100.

Shahi SR, Zadbuke NS, Gulecha B, Shivanikar SS, Shinde SB. Design and development of controlled porosity osmotic tablet of diltiazem hydrochloride. J Adv Pharm Technol Res. 2012;3(4):229-36. doi: 10.4103/2231-4040.104714, PMID 23378944.

Sanap LS, Savkare AD. Controlled porosity osmotic pump a review. Int J Pharm Res Dev. 2014;5(12):71-80.

Kurapati P, Chinni S. Development and optimization of rabeprazole chrono-modulated drug delivery systems. Int J App Pharm. 2024;16(3):332-41. doi: 10.22159/ijap.2024v16i3.50189.

Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019;11(3):132. doi: 10.3390/pharmaceutics11030132, PMID 30893899.

Ubaidulla U, Senthilkumar B, Ahmad FJ, Khar RK. Studies on suspension of nimesulide solid dispersion: development characterization and in vivo evaluation. Indian J Pharm Sci. 2005;67(4):422-6.

Ravindra KK, Chintan VP, Aditee CP. Validation of novel analytical RP-HPLC method for determination of formoterol fumarate and budesonide in inhalation suspension pharmaceutical dosage form. Res J Pharm Technol. 2021;14(8). doi: 10.52711/0974-360X.2021.00761.

Liu H, Zhou LL, Wei LL, Hong Guo G, Nie SF, Yang XG. Preparation of budesonide poly (ethylene oxide) solid dispersions using supercritical fluid technology. Drug Dev Ind Pharm. 2007;33(9):959-66. doi: 10.1080/03639040601134181, PMID 17891582.

Bharathi Priya K, Kulathuran Pillai K, Nalini CN, Udhumansha U. Formulation and characterization of 5-fluorouracil and metformin biodegradable nanospheres for treating colon cancer. Futur J Pharm Sci. 2024;10(1):145. doi: 10.1186/s43094-024-00713-2.

Huang Y, YU H, Xiao C. pH-sensitive cationic guar gum/poly (acrylic acid) polyelectrolyte hydrogels: swelling and in vitro drug release. Carbohydrate Polymers. 2007;69(4):774-83. doi: 10.1016/j.carbpol.2007.02.016.

Ubaidulla U, Sinha P, Sangavi T, Rathnam G. Development of silymarin entrapped chitosan phthalate nanoparticles for targeting colon cancer. J Nat Rem. 2022;22(4):659-71. doi: 10.18311/jnr/2022/29816.

Prashant LP, Sunil VA, Darshan RT. Formulation characterization and in vitro dissolution studies of metadoxine tablets prepared by various granulation methods. J Pharm Allied Sci. 2021;10(2).2712-19. doi: 10.22270/jmpas.v10i2.1066.

Tripathi P, Ubaidulla U, Roop Kishan Khar V. Floating drug delivery system. IJRDPL. 2012;1(4):1-10.

Jeong YI, Ohno T, HU Z, Yoshikawa Y, Shibata N, Nagata S. Evaluation of an intestinal pressure controlled colon delivery capsules prepared by a dipping method. J Control Release. 2001;71(2):175-82. doi: 10.1016/s0168-3659(01)00211-5, PMID 11274749.

Vaishnavi BP, Raosaheb SS, Pooja SS, Shubham RP, Aniket JP. Formulation and in vitro evaluation of oral colon targeted sustained released tablet of budesonide. Turk J Physiother Rehabil. 2022;32:3.

Sawada T, Tsuruoka T, Ueda N, Marubayashi H, Nojima S, Morikawa J. Thermally conductive molecular assembly composed of an oligo(ethylene glycol)-modified filamentous virus with improved solubility and resistance to organic solvents. Polym J. 2020;52(7):803-11. doi: 10.1038/s41428-020-0328-7.

Pandey M, Choudhury H, Sahleni K, Chetty Annan N, Bhattamisra SK, Gorain B. Budesonide loaded pectin/polyacrylamide hydrogel for sustained delivery: fabrication characterization and in vitro release kinetics. Molecules. 2021;26(9):2704. doi: 10.3390/molecules26092704, PMID 34062995.

Mahapatra AP, Saraswat R, Botre M, Paul B, Prasad N. Application of response surface methodology (RSM) in statistical optimization and pharmaceutical characterization of a patient compliance effervescent tablet formulation of an antiepileptic drug levetiracetam. Futur J Pharm Sci. 2020;6(1):82. doi: 10.1186/s43094-020-00096-0.

Michailidou G, Papageorgiou GZ, Bikiaris DN. β-cyclodextrin inclusion complexes of budesonide with enhanced bioavailability for COPD treatment. Appl Sci. 2021;11(24):12085. doi: 10.3390/app112412085.

Jara MO, Warnken ZN, Williams RO. Amorphous solid dispersions and the contribution of nanoparticles to in vitro dissolution and in vivo testing: niclosamide as a case study. Pharmaceutics. 2021;13(1):97. doi: 10.3390/pharmaceutics13010097, PMID 33466598.

Chaudhary A, Tiwari N, Jain V, Singh R. Microporous bilayer osmotic tablet for colon-specific delivery. Eur J Pharm Biopharm. 2011;78(1):134-40. doi: 10.1016/j.ejpb.2011.01.004.

Uthumansha U, Prabahar K, Gajapathy DB, El-Sherbiny M, Elsherbiny N, Qushawy M. Optimization and in vitro characterization of telmisartan loaded sodium alginate beads and its in vivo efficacy investigation in hypertensive induced animal model. Pharmaceutics. 2023;15(2):709. doi: 10.3390/pharmaceutics15020709, PMID 36840031.

Ibrahim IM. Advances in polysaccharide-based oral colon targeted delivery systems: the journey so far and the road ahead. Cureus. 2023 Jan 11;15(1):e33636. doi: 10.7759/cureus.33636, PMID 36788847.

Garcia MA, Varum F, Al-Gousous J, Hofmann M, Page S, Langguth P. In vitro methodologies for evaluating colon-targeted pharmaceutical products and industry perspectives for their applications. Pharmaceutics. 2022 Jan 26;14(2):291. doi: 10.3390/pharmaceutics14020291, PMID 35214024.

Srikar G, Rani AP. Tenofovir loaded poly (lactide-co-glycolide) nanocapsules: formulation optimization by desirability functions approach. Indian J Pharm Educ Res. 2020;54(2S):s230-40. doi: 10.5530/ijper.54.2s.79.

Grandhi S, Rani AP, Pathuri R. Voriconazole solid lipid nanoparticles: optimization of formulation and process parameters. Res J Pharm Technol. 2018;11(7):2829-35. doi: 10.5958/0974-360X.2018.00522.X.

Soliman L, Ibrahim W. Effect of coating thickness and polyethylene glycols molecular weight on diltiazem hydrochloride release from controlled porosity osmotic pump tablets. Res J Pharm Technol. 2022;15(9):4043-7. doi: 10.52711/0974-360X.2022.00678.

Gundu R, Pekamwar S, Shelke S, Kulkarni D, Shep S. Development optimization and pharmacokinetic evaluation of biphasic extended release osmotic drug delivery system of trospium chloride for promising application in the treatment of overactive bladder. Future J Pharm Sci. 2021;7(1):1-20.

Niranjan GK, Sima S, Balaji M, Omprakash S, Thomas JW. Anovel dissolution media for testing drug release from a nanostructured polysaccharide based colon-specific drug delivery system: an approach to alternative colon media. Int J Nanomedicine. 2016 Mar 17;11:1089-95. doi: 10.2147/IJN.S97177.

Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter. 2011;1(1):57-65. doi: 10.4161/biom.1.1.17717, PMID 23507727.

Sahoo CK, Sahoo NK, Rao SR, Sudhakar M, Satyanarayana K. A review on controlled porosity osmotic pump tablets and its evaluation. Bull Fac Pharm Cairo Univ. 2015;53(2):195-205. doi: 10.1016/j.bfopcu.2015.10.004.

Bharathi Priya K, Kulathuran Pillai K, Nalini CN, Udhumansha U. Design and optimizing of metformin and 5-fluorouracil co-loaded nanospheres by box behnken experimental design for the treatment of colorectal cancer. Int J Curr Sci Res Rev. 2024;07(07):4717-26. doi: 10.47191/ijcsrr/V7-i7-16.

Pandey S, Vijayendra Swamy SM, Ubaid Ulla UM, Gupta A, Patel H, Yadav JS. Cell line and augument cellular uptake study of statistically optimized sustained release capecitabine loaded eudragit S100/PLGA(poly(lacticco- glycolic acid)) nanoparticles for colon targeting. Curr Drug Deliv. 2017;14(6):887-99. doi: 10.2174/1567201813666160817150621, PMID 27538461.